Bluebird bio Inc Total Liabilities
Bluebird bio Inc total liabilities. Based on the latest financial reports, Bluebird bio Inc (BLUE) has total liabilities worth $353.82 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BLUE financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Bluebird bio Inc (2011–2024)
Total liabilities of Bluebird bio Inc from 2011 to 2024. This chart illustrates how Bluebird bio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Bluebird bio Inc (BLUE) investment intensity to see how much of total assets are deployed in long-term investments.
Bluebird bio Inc Competitors by Total Liabilities
The table below lists competitors of Bluebird bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Promateris SA
RO:PPL
|
Romania | RON118.86 Million |
|
W5 Solutions AB
ST:W5
|
Sweden | Skr683.25 Million |
|
Sietel Ltd
AU:SSL
|
Australia | AU$9.16 Million |
|
Quartiers Properties AB
ST:QUART
|
Sweden | Skr218.07 Million |
|
Hurriyet Gazetecilik ve Matbaacilik AS
IS:HURGZ
|
Turkey | TL2.59 Billion |
|
Tuniu Corp
NASDAQ:TOUR
|
USA | $90.98 Million |
|
Hvidbjerg Bank
CO:HVID
|
Denmark | Dkr2.19 Billion |
|
VivoPower PLC
NASDAQ:VIVO
|
USA | $69.78 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Bluebird bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Bluebird bio Inc total assets.
Liquidity & Leverage Metrics
Bluebird bio Inc Total Liabilities Ratios Explained
Bluebird bio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bluebird bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bluebird bio Inc (2011–2024)
The table below shows the annual total liabilities of Bluebird bio Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $491.77 Million | +15.81% |
| 2023-12-31 | $424.62 Million | +18.43% |
| 2022-12-31 | $358.56 Million | +63.34% |
| 2021-12-31 | $219.52 Million | -48.49% |
| 2020-12-31 | $426.20 Million | -3.67% |
| 2019-12-31 | $442.43 Million | +23.66% |
| 2018-12-31 | $357.77 Million | +29.10% |
| 2017-12-31 | $277.13 Million | +11.44% |
| 2016-12-31 | $248.68 Million | +63.78% |
| 2015-12-31 | $151.84 Million | +131.88% |
| 2014-12-31 | $65.48 Million | -9.96% |
| 2013-12-31 | $72.72 Million | -41.85% |
| 2012-12-31 | $125.07 Million | +44.38% |
| 2011-12-31 | $86.62 Million | -- |
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more